We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
12 own
21 watching
Current Price
$56
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
28,226.44M
52-Week High
89.7
52-Week Low
49.83
Average Volume
1.2M
Dividend Yield
0.013455
P/E Ratio
32.5274
Market Capitalization28,226.44M
52-Week High89.7
52-Week Low49.83
Average Volume1.2M
Dividend Yield0.013455
P/E Ratio32.5274
What does the Stockal+Disclaimer.pdf do?
Baxter International Inc. provides a portfolio of renal and hospital products. The company operates through two segments, Hospital Products and Renal. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers products for various treatment continuums, such as technologies and therapies for peritoneal dialysis, hemodialysis, continuous renal replacement therapy, and additional dialysis services. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. It offers its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. The company has a collaboration agreement with JW Holdings Corporation to co-develop and distribute parenteral nutritional products containing a novel formulation of omega 3 lipids; and agreement with Celerity Pharmaceutical, LLC to develop certain acute care generic injectable premix and oncolytic molecules. It also has a strategic partnership with ScinoPharm Taiwan, Ltd. to develop, manufacture, and commercialize five injectable drugs for cancer treatments, such as lung cancer, multiple myeloma, and breast cancer, as well as medication to treat nausea and vomiting, and side effects of chemotherapy. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Business Wire
13days ago
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on January 3, 2023, to shareholders of record as of December 2, 2022. The indicated annual...
Globe Newswire
26days ago
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX: EDT) (Spectral or the Company) is pleased to announce that it has closed its previously announced prospectus offering of units (the...
Zolmax
1month ago
Stock analysts at Jefferies Financial Group initiated coverage on shares of Baxter International (NYSE:BAX Get Rating) in a research note issued to investors on Wednesday, The Fly reports. The brokerage set a hold rating and a $62.00 price target on the medical instruments suppliers stock. Jefferies...
Ticker Report
1month ago
Baxter International (NYSE:BAX Get Rating) had its target price decreased by Morgan Stanley from $72.00 to $70.00 in a report released on Tuesday , Marketbeat reports. Morgan Stanley currently has an overweight rating on the medical instruments suppliers stock. Several other research ...
Business Wire
2 months ago
Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its new Novum IQ syringe infusion pump (SYR) with Dose IQ Safety Software, representing Baxters latest developments for...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$56
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00